Allogenic

Basiliximab Anti-IL-2 CD25 Allogeneic organ transplantation... 

Arencibia, I., Pedari, L., Sundqvist, K.G. (1987). Induction of motility and alteration of surface membrane polypeptides in lymphocytes by contact with autologous and allogenic fibroblasts. Expt. Cell Res. 172, 124-133. 

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for SCD. The best candidates are children with SCD who are younger than 16 years of age with severe complications who have an identical H LA-matched donor, usually a sibling. The transplant-related mortality rate is between 5% and 10%, and graft rejection is approximately 10%. Other risks include secondary malignancies, development of seizures or intracranial bleeding, and infection in the immediate posttransplant period.6,25,32,33... 

Invasive molds, particularly Aspergillus, have become an increasingly important complication of cancer therapy and organ transplantation. Patients with acute leukemia and recipients of allogeneic hematopoietic cell transplants are at especially high risk for invasive aspergillosis due to prolonged neutropenia and deficiencies in cell-mediated immunity associated... 

Allogeneic hematopoietic stem cell transplantation (HSCT) has been used in the treatment of pediatric AML in first complete remission. In most clinical trials, the availability of HLA-matched sibling donors determined whether patients underwent HSCT as postremission treatment. To facilitate this process, it is important to obtain HLA typing on all younger patients with AML and siblings shortly after diagnosis. Patients who do not have an HLA-matched sibling will proceed to postremission therapy. 

Transplant-related mortality following matched-sibling allogeneic HSCT is 20% to 30% in most series. Complications from transplantation increase with age therefore, patients older than 60 years of age are uncommonly considered to receive an allogeneic HSCT. Since the average age of AML patients is 65 years, it is obvious that most patients with this disease are not candidates for this form of therapy. 

HSCT in first remission is often recommended for patients with a matched-sibling donor because of the lower relapse rate with transplant versus postremission chemotherapy. However, only 30% of patients will have an HLA-matched sibling. Some types of AML patients may be curable with conventional-dose chemotherapy alone. Thus indiscriminate use of allogeneic HSCT could reduce the rate and quality of survival in these individuals. 

Allogeneic stem cell transplantation is the only curative treatment for chronic myelogenous leukemia (CML). 

Early in the diagnosis, patients should be evaluated for allogeneic stem cell transplantation. Ideal candidates include younger patients in chronic-phase CML who have an HLA-matched related or unrelated donor. 

Compare the different types of HCTs, specifically (a) the types of donors (i.e., autologous and allogeneic), (b) the source of hematopoietic cells (i.e., umbilical cord, peripheral blood progenitor cells, and bone marrow), and (c) the type of preparative regimen (i.e., myeloablative and nonmyeloablative). 

An autologous HCT involves the infusion of a patient s own hematopoietic cells and allows for the administration of higher doses of chemotherapy, radiation, or both to treat the malignancy. Infusion of another s hematopoietic cells is an allogeneic HCT these cells can be from donors related or unrelated to the recipient. 

For an allogeneic HCT, the recipient and the donor are dissimilar genetically unless they are identical twins (referred to as a syngeneic HCT). The tissue transplanted is immunologi-cally active, and thus there is potential for bidirectional graft... 

---